Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo

Nature Medicine

Volumn 20, Issue 2, 2014, Pages 143-151

  Dilillo, David J ^a   Tan, Gene S ^b   Palese, Peter ^b   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY COMPLEX; CELL LINE; CHICK EMBRYO; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 84893797938     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3443     Document Type: Article

References (53)

1. World Health Organization. Influenza (Seasonal) Fact sheet 211 http://www.who.int/mediacentre/factsheets/fs211/en/(2009).
2. Ahmed, R., Oldstone, M.B. & Palese, P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 8, 1188-1193 (2007).
3. Martinez, O., Tsibane, T. & Basler, C.F. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int. Rev. Immunol. 28, 69-92 (2009).
4. Couch, R.B. & Kasel, J.A. Immunity to influenza in man. Annu. Rev. Microbiol. 37, 529-549 (1983).
5. Wang, T.T. & Palese, P. Biochemistry. Catching a moving target. Science 333, 834-835 (2011).
6. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
7. Knossow, M. et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302, 294-298 (2002).
8. Wiley, D.C., Wilson, I.A. & Skehel, J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373-378 (1981).
9. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
10. Barbey-Martin, C. et al. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 294, 70-74 (2002).
11. Ekiert, D.C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
12. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
13. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
14. Abboud, N. et al. A requirement for FcgR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207, 2395-2405 (2010).
15. Bournazos, S., Chow, S.K., Abboud, N., Casadevall, A. & Ravetch, J.V. Human IgG Fc domain engineering enhances anti-toxin neutralizing antibody activity. J. Clin. Invest. (in the press).
16. Schmitz, N. et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 42, 863-869 (2012).
17. Huber, V.C., Lynch, J.M., Bucher, D.J., Le, J. & Metzger, D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166, 7381-7388 (2001).
18. Nimmerjahn, F. & Ravetch, J.V. Fc receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
19. Nimmerjahn, F. & Ravetch, J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
20. Tan, G.S. et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179-6188 (2012).
21. Li, G.M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109, 9047-9052 (2012).
22. Reale, M.A. et al. Characterization of monoclonal antibodies specific for sequential influenza A/PR/8/34 virus variants. J. Immunol. 137, 1352-1358 (1986).
23. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
24. Smith, P., DiLillo, D.J., Bournazos, S., Li, F. & Ravetch, J.V. Mouse model recapitulating human Fc receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181-6186 (2012).
25. Manicassamy, B. et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6, e1000745 (2010).
26. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837-1848 (2013).
27. Jegaskanda, S., Weinfurter, J.T., Friedrich, T.C. & Kent, S.J. Antibody-dependent cellular cytotoxicity (ADCC) is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87, 5512-5522 (2013).
28. Srivastava, V. et al. Identification of dominant ADCC epitopes on hemagglutinin antigen of pandemic H1N1 influenza virus. J. Virol. 87, 5831-5840 (2013).
29. Alter, G., Malenfant, J.M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15-22 (2004).
30. Nimmerjahn, F. & Ravetch, J.V. Analyzing antibody-Fc-receptor interactions. Methods Mol. Biol. 415, 151-162 (2008).
31. El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022-1031 (2011).
32. Jegerlehner, A., Schmitz, N., Storni, T. & Bachmann, M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172, 5598-5605 (2004).
33. Tedder, T.F., Baras, A. & Xiu, Y. Fc receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28, 351-364 (2006).
34. Nordstrom, J.L. et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc receptor binding properties. Breast Cancer Res. 13, R123 (2011).
35. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
36. Yang, X. et al. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol. Ther. 21, 91-100 (2013).
37. Belser, J.A., Katz, J.M. & Tumpey, T.M. The ferret as a model organism to study influenza A virus infection. Dis. Model. Mech. 4, 575-579 (2011).
38. Nimmerjahn, F. & Ravetch, J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19, 239-245 (2007).
39. Nimmerjahn, F. & Ravetch, J.V. FcRs in health and disease. Curr. Top. Microbiol. Immunol. 350, 105-125 (2011).
40. Barkas, T. & Watson, C.M. Induction of an Fc conformational change by binding of antigen: the generation of protein A-reactive sites in chicken immunoglobulin. Immunology 36, 557-561 (1979).
41. Kilàr, F. & Zavodszky, P. Non-covalent interactions between Fab and Fc regions in immunoglobulin G molecules. Hydrogen-deuterium exchange studies. Eur. J. Biochem. 162, 57-61 (1987).
42. Torres, M., Fernandez-Fuentes, N., Fiser, A. & Casadevall, A. The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J. Biol. Chem. 282, 13917-13927 (2007).
43. Oda, M., Kozono, H., Morii, H. & Azuma, T. Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int. Immunol. 15, 417-426 (2003).
44. Schlessinger, J., Steinberg, I.Z., Givol, D., Hochman, J. & Pecht, I. Antigen-induced conformational changes in antibodies and their Fab fragments studied by circular polarization of fluorescence. Proc. Natl. Acad. Sci. USA 72, 2775-2779 (1975).
45. Tong, H. et al. Peptide-conjugation induced conformational changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography. Sci. Rep. 3, 1089 (2013).
46. Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J.V. FcRBV chain deletion results in pleiotrophic effector cell defects. Cell 76, 519-529 (1994).
47. Takai, T., Ono, M., Hikida, M., Ohmori, H. & Ravetch, J.V. Augmented humoral and anaphylactic responses in FcRII-deficient mice. Nature 379, 346-349 (1996).
48. Ioan-Facsinay, A. et al. FcRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16, 391-402 (2002).
49. Hazenbos, W.L. et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcRIII (CD16) deficient mice. Immunity 5, 181-188 (1996).
50. Nimmerjahn, F. et al. FcRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. USA 107, 19396-19401 (2010).
51. Li, F. & Ravetch, J.V. Inhibitory Fc receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034 (2011).
52. Nimmerjahn, F., Bruhns, P., Horiuchi, K. & Ravetch, J.V. FcRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41-51 (2005).
53. Wang, T.T. et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6, e1000796 (2010).